Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2014 December;105(6 Suppl 3) > Minerva Medica 2014 December;105(6 Suppl 3):9-13

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  PNEUMOLAB PROCEEDINGS Freefree

Minerva Medica 2014 December;105(6 Suppl 3):9-13

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Multi-platform lung tumors profiling identifies actionable targets and unveils series of uncommon/rare diseases

Stella G. M.

Laboratory of Biochemistry and Genetics Pulmonology Unit, Department of Molecular Medicine, University and Fondazione IRCCS, Policlinico San Matteo di Pavia, Pavia, Italy


PDF


Lung cancer is characterized by a number of genetic alterations, of which a proportion is still unknown. Nevertheless numerous pathogenetically important driver changes have been already been detected in a substantial fraction of patients and translated into a system to improve detection and outcome of the disease. In this scenario, the Lung Cancer Mutation Consortium developed an ambitious project aimed to perform on large scale the molecular profile of lung adenocarcinoma in order to identify actionable targets. The review analyses the paper - recently published showing study findings- taking into account if the car and not the driver matters in lung cancer precision management.

inizio pagina